REVIEW article
Front. Cardiovasc. Med.
Sec. Cardiovascular Epidemiology and Prevention
This article is part of the Research TopicEnvironmental Determinants of Cardiovascular Health: Interactions with Lifestyle and Socioeconomic FactorsView all 13 articles
Preventing Premature Cardiovascular Mortality: The Role of Lifestyle Interventions and Pharmacotherapy - A Narrative Review
Provisionally accepted- 1American University of Beirut, Beirut, Lebanon
- 2Lebanese American University, Beirut, Lebanon
- 3University of Balamand, Balamand, Lebanon
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cardiovascular diseases (CVD), including coronary heart disease, cerebrovascular disease, and peripheral artery diseases, are the leading global cause of premature mortality in adults. Addressing CVD aligns with the United Nations Sustainable Development Goals aiming to reduce premature deaths by one-third by 2030 through lifestyle and pharmacological interventions. Major risk factors for CVD are categorized into lifestyle and genetic factors. Lifestyle factors such as elevated cholesterol, hypertension, high body mass index, smoking, poor dietary habits, and physical inactivity significantly increase CVD mortality. Conversely, genetic predisposition strongly influences individual risk, often amplified by unhealthy behaviors. Primary prevention strategies, including adherence to Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diet (MD), regular physical activity, and smoking cessation, have demonstrated effectiveness in reducing CVD incidence and mortality. Secondary prevention emphasizes pharmacological interventions, specifically aspirin and statin therapies, non-statin agents, antihypertensive, all of which significantly decrease recurrent cardiovascular events among high-risk individuals. Although cardiovascular screening practices remain debated, targeted screening informed by precision medicine approaches and artificial intelligence shows promise in stratifying risk effectively. This review synthesizes evidence on these preventive strategies, underscoring their integrated role in reducing premature CVD-related mortality, while recognizing the need for further implementation research to optimize preventive healthcare outcomes.
Keywords: Cardiovascular disease prevention, premature mortality, lifestyle interventions, Pharmacotherapy, risk stratification
Received: 12 Jul 2025; Accepted: 25 Nov 2025.
Copyright: © 2025 Haber, Nasr, El Etry and Nasr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Marc Haber
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
